Collegium Pharma (NASDAQ: COLL) reported Q4 EPS of ($0.07), $0.03 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $74.2 million versus the consensus estimate of $73.33 million.

Financial Guidance for 2020

The Company reiterates its full-year 2020 financial guidance, initially provided on January 7, 2020:

• Xtampza ER revenues are expected in the range of $150.0 million to $160.0 million.
• Nucynta Franchise revenues are expected in the range of $170.0 million to $180.0 million.
• Total operating expenses are expected in the range of $130.0 million to $140.0 million.

In addition, the Company provides the following full-year 2020 financial guidance:

• Non-GAAP adjusted income is expected in the range of $125.0 million to $140.0 million

For earnings history and earnings-related data on Collegium Pharma (COLL) click here.